tissue-targeting delivery
for local action

Ulcerative colitis and Crohn’s disease, the two most common forms of inflammatory bowel disease (IBD), are both chronic, relapsing diseases characterized by the inflammation of segments of the gastrointestinal tract.

In North America, more than 2 million people suffer from these debilitating conditions.

More than 40% of IBD patients do not tolerate or respond well to current therapies. Currently available medications alleviate inflammation but do not prevent long-term complications. There is a strong need to broaden the therapeutic arsenal with novel, orally-administered therapeutic modalities, which could become alternatives to biologic medications.

The primary indication targeted by giiant is moderate-to-severe, active ulcerative colitis. giiant’s lead compound GT-2108 is a gut-restricted, colon-specific PDE4 prodrug inhibitor. GT-1908 is also a gut-restricted PDE4 inhibitor prodrug able to deliver the active drug more proximally, making it a suitable candidate for the treatment of Crohn’s disease.

Table of pipeline

Drug candidatetargetGut-restrictedTissue Specificdiscoverypreclinicalphase 1phase 2phase 3
GT-1908PDE4check-iconterminal ileumarrow-icon

Drug Hunting Club

giiant pharma is continually looking for new GI-related technologies. giiant created a Drug Hunting Club to identify new, promising opportunities to in-license. If you have a technology to propose that is aligned with our lead asset GT-2108, please contact us.